Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept.
CONCLUSIONS: RA patients with TCZ do not have a medium-term excess of CV risk in patients compared with ETN.
PMID: 29303702 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
More News: Actemra | Arthritis | Cardiology | Cardiovascular | Databases & Libraries | Enbrel | Heart | Heart Attack | Italy Health | Rheumatoid Arthritis | Rheumatology | Stroke | Study